keyword
MENU ▼
Read by QxMD icon Read
search

Cancer pain, neuropathy, pain

keyword
https://www.readbyqxmd.com/read/27884691/aapt-diagnostic-criteria-for-chronic-cancer-pain-conditions
#1
REVIEW
Judith A Paice, Matt Mulvey, Michael Bennett, Patrick M Dougherty, John T Farrar, Patrick W Mantyh, Christine Miaskowski, Brian Schmidt, Thomas J Smith
: Chronic cancer pain is a serious complication of malignancy or its treatment. Currently, no comprehensive, universally accepted cancer pain classification system exists. Clarity in classification of common cancer pain syndromes would improve clinical assessment and management. Moreover, an evidence-based taxonomy would enhance cancer pain research efforts by providing consistent diagnostic criteria, ensuring comparability across clinical trials. As part of a collaborative effort between the Analgesic, Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks (ACTTION) and the American Pain Society (APS), the ACTTION-APS Pain Taxonomy (AAPT) initiative worked to develop the characteristics of an optimal diagnostic system...
November 21, 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/27854104/new-practical-approaches-to-chemotherapy-induced-neuropathic-pain-prevention-assessment-and-treatment
#2
REVIEW
Neil Majithia, Charles L Loprinzi, Thomas J Smith
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most disabling and demoralizing problems that arise for cancer survivors. When investigating symptoms of numbness, tingling, or pain in the extremities, it is critical to determine whether the problem is neuropathic, somatic, or mixed. If the diagnosis is CIPN, it is important to weigh the potential benefits and harms of possible treatment options, and to devise an evidence-based multimodality treatment program. Such programs may include mixtures of opioid and nonopioid adjunctive medications, based on evidence from CIPN trials, and also extrapolation from trials in patients with other neuropathic pain syndromes-although such extrapolating must be done with caution, since other syndromes sometimes respond to agents that CIPN does not respond to...
November 15, 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27846661/-physical-therapy-for-chemotherapy-induced-peripheral-neuropathy-in-pediatric-oncology
#3
M Jung, N Rein, B Fuchs
Background: Chemotherapy-induced peripheral neuropathy is a frequent side-effect of drugs that are used in the treatment of cancer. Affected individuals can suffer from motor, sensory or autonomy nerve damage. Further medication is used for the treatment of CIPN which can cause further side-effects. Patients should be offered physical therapy treatment to relieve the symptoms. Objective: The aim of this article is to give an overview of available literature investigating physical therapy in CIPN in pediatric oncology...
November 2016: Klinische Pädiatrie
https://www.readbyqxmd.com/read/27844290/potentiation-of-paclitaxel-induced-pain-syndrome-in-mice-by-angiotensin-i-converting-enzyme-inhibition-and-involvement-of-kinins
#4
Indiara Brusco, Cássia Regina Silva, Gabriela Trevisan, Camila de Campos Velho Gewehr, Flávia Karine Rigo, Lidia La Rocca Tamiozzo, Mateus Fortes Rossato, Raquel Tonello, Gerusa Duarte Dalmolin, Daniela de Almeida Cabrini, Marcus Vinícius Gomez, Juliano Ferreira, Sara Marchesan Oliveira
Paclitaxel is a chemotherapeutic agent used to treat solid tumours. However, it causes an acute and neuropathic pain syndrome that limits its use. Among the mechanisms involved in neuropathic pain caused by paclitaxel is activation of kinin receptors. Angiotensin converting enzyme (ACE) inhibitors can enhance kinin receptor signalling. The goal of this study was to evaluate the role of kinins on paclitaxel-associated acute pain syndromes (P-APS) and the effect of ACE inhibition on P-APS and paclitaxel-associated chronic peripheral neuropathy (P-CPN) in mice...
November 14, 2016: Molecular Neurobiology
https://www.readbyqxmd.com/read/27811127/collet-sicard-syndrome-a-rare-but-important-presentation-of-internal-jugular-vein-thrombosis
#5
Shermyn Neo, Kim En Lee
We describe a rare neurological presentation of internal jugular vein thrombosis induced by central venous catheter placement in a patient with cancer. A 71-year-old man gave a 3-week history of dysphagia and dysarthria with left-sided neck pain and headache. He was receiving chemotherapy for appendiceal adenocarcinoma. On examination, he had left 9th-12th cranial neuropathies, manifesting as voice hoarseness, decreased palatal movement, absent gag reflex, weakness of scapular elevation and left-sided tongue wasting...
November 3, 2016: Practical Neurology
https://www.readbyqxmd.com/read/27803912/efficacy-of-japanese-traditional-kampo-medicine-for-treating-chemotherapy-induced-peripheral-neuropathy-a-retrospective-case-series-study
#6
Yumiko Kimata, Keiko Ogawa, Hideki Okamoto, Atsushi Chino, Takao Namiki
AIM: To investigate Japanese traditional (Kampo) medicine's effectiveness on cancer chemotherapy-induced peripheral neuropathy (CIPN), we carried out this retrospective study. METHODS: By searching our outpatient database of 3154 patients who consulted our outpatient clinic of Japanese-Oriental (Kampo) Medicine at Chiba University Hospital from November 2005 to December 2010, a total of 281 patients diagnosed with cancer were identified. Twenty-four patients out of the 281 patients identified met the following three conditions and were eligible for further investigation of the effectiveness of Kampo treatment: At least one course of cancer chemotherapy had been administered; numbness and pain appeared after the chemotherapy; and CIPN was diagnosed before they were given Kampo treatment...
October 16, 2016: World Journal of Clinical Cases
https://www.readbyqxmd.com/read/27798187/cd8-t-cells-and-endogenous-il-10-are-required-for-resolution-of-chemotherapy-induced-neuropathic-pain
#7
Karen Krukowski, Niels Eijkelkamp, Geoffroy Laumet, C Erik Hack, Yan Li, Patrick M Dougherty, Cobi J Heijnen, Annemieke Kavelaars
: Chemotherapy-induced peripheral neuropathy (CIPN), characterized by pain and numbness in hands and feet, is a common side effect of cancer treatment. In most patients, symptoms of CIPN subside after treatment completion. However, in a substantial subgroup, CIPN persists long into survivorship. Impairment in pain resolution pathways may explain persistent CIPN. We investigated the contribution of T cells and endogenous interleukin (IL)-10 to resolution of CIPN. Paclitaxel-induced mechanical allodynia was prolonged in T-cell-deficient (Rag1(-/-)) mice compared with wild-type (WT) mice...
October 26, 2016: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/27789344/behavioral-and-electromyographic-assessment-of-oxaliplatin-induced-motor-dysfunctions-evidence-for-a-therapeutic-effect-of-allopregnanolone
#8
Omar Taleb, Fateh Bouzobra, Hava Tekin-Pala, Laurence Meyer, Ayikoé, G Mensah-Nyagan, Christine Patte-Mensah
The antineoplastic oxaliplatin (OXAL) is pivotal for metastatic cancer treatments. However, OXAL evokes sensory and motor side-effects including pain, muscle weakness, motor nerve fiber dysfunctions/neuropathies that significantly impact patients' lives. Therefore, preclinical investigations are struggling to characterize effective analgesics against OXAL-induced painful/sensory symptoms but surprisingly, OXAL-evoked motor dysfunctions received little attention although these neurological symptoms are also disabling for patients...
October 24, 2016: Behavioural Brain Research
https://www.readbyqxmd.com/read/27787567/patient-s-quality-of-life-after-high-dose-radiation-therapy-for-thoracic-carcinomas-changes-over-time-and-influence-on-clinical-outcome
#9
Christina Schröder, Rita Engenhart-Cabillic, Hilke Vorwerk, Michael Schmidt, Winfried Huhnt, Eyck Blank, Dietrich Sidow, André Buchali
PURPOSE: Quality of life (QoL) is an important factor in patient care. This analysis is focused on QoL before and after radio(chemo)therapy in patients with thoracic carcinomas, as well as on its influence on clinical follow-up and survival, and the correlation with treatment-related toxicities. MATERIALS AND METHODS: The analysis included 81 patients with intrathoracic carcinoma receiving radio(chemo)therapy. For analysis of QoL, the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the lung cancer-specific supplement (EORTC QLQ-LC13) were used...
October 27, 2016: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/27776522/inositol-1-4-5-trisphosphate-receptor-type-1-autoantibodies-in-paraneoplastic-and-non-paraneoplastic-peripheral-neuropathy
#10
Sven Jarius, Marius Ringelstein, Jürgen Haas, Irina I Serysheva, Lars Komorowski, Kai Fechner, Klaus-Peter Wandinger, Philipp Albrecht, Harald Hefter, Andreas Moser, Eva Neuen-Jacob, Hans-Peter Hartung, Brigitte Wildemann, Orhan Aktas
BACKGROUND: Recently, we described a novel autoantibody, anti-Sj/ITPR1-IgG, that targets the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in patients with cerebellar ataxia. However, ITPR1 is expressed not only by Purkinje cells but also in the anterior horn of the spinal cord, in the substantia gelatinosa and in the motor, sensory (including the dorsal root ganglia) and autonomic peripheral nervous system, suggesting that the clinical spectrum associated with autoimmunity to ITPR1 may be broader than initially thought...
October 24, 2016: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/27749615/quantification-of-chronic-oxaliplatin-induced-hypoesthesia-in-two-areas-of-the-hand
#11
M Andriamamonjy, J-B Delmotte, F Savinelli, H Beaussier, F Coudore
INTRODUCTION: Oxaliplatin is a platinum derivate widely used in cancer treatment but producing dose-limiting peripheral neurotoxicity. Acute neuropathy is characterized by a transient cold-induced distal allodynia whereas chronic neuropathy leads to sensory loss. In order to design a method for quantitative assessment of oxaliplatin-induced peripheral neuropathy, we developed a study that aims to characterize the most appropriate skin area of the hand to perform sensory tests. METHODS: We included patients treated during at least 6 months with oxaliplatin...
October 1, 2016: Journal of Clinical Neurophysiology: Official Publication of the American Electroencephalographic Society
https://www.readbyqxmd.com/read/27613370/laser-acupuncture-attenuates-oxaliplatin-induced-peripheral-neuropathy-in-patients-with-gastrointestinal-cancer-a-pilot-prospective-cohort-study
#12
Yueh-Ling Hsieh, Li-Wei Chou, Shao-Fu Hong, Fei-Chi Chang, Szu-Wen Tseng, Chi-Chou Huang, Ching-Hsiang Yang, Chen-Chia Yang, Wei-Feng Chiu
BACKGROUND: Oxaliplatin is a platinum compound that is widely used in the treatment of some solid tumours. Oxaliplatin-induced peripheral neuropathy (OIPN) in the upper and lower extremities is the major adverse side effect and represents the main dose-limiting factor of this drug. The aim of this single-arm study was to evaluate the feasibility and effects of laser acupuncture (LA) in the treatment of OIPN in patients with advanced gastrointestinal cancers. METHODS: 17 gastrointestinal cancer survivors (14 colorectal and 3 gastric cancers), who had been treated with oxaliplatin-based chemotherapies, were recruited...
October 2016: Acupuncture in Medicine: Journal of the British Medical Acupuncture Society
https://www.readbyqxmd.com/read/27612466/a-randomised-placebo-controlled-trial-assessing-the-efficacy-of-an-oral-b-group-vitamin-in-preventing-the-development-of-chemotherapy-induced-peripheral-neuropathy-cipn
#13
Janet M Schloss, Maree Colosimo, Caroline Airey, Paul Masci, Anthony W Linnane, Luis Vitetta
INTRODUCTION: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect resulting from neurotoxic chemotherapeutic agents. This study aimed to assess the efficacy and safety of an oral B group vitamin compared to placebo, in preventing the incidence of CIPN in cancer patients undergoing neurotoxic chemotherapy. METHODS: A pilot, randomised, placebo-controlled trial was conducted. Newly diagnosed cancer patients prescribed with taxanes, oxaliplatin or vincristine were invited to participate...
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27565279/a-promis-measure-of-neuropathic-pain-quality
#14
Robert L Askew, Karon F Cook, Francis J Keefe, Cindy J Nowinski, David Cella, Dennis A Revicki, Esi M Morgan DeWitt, Kaleb Michaud, Dace L Trence, Dagmar Amtmann
OBJECTIVES: Neuropathic pain (NP) is a consequence of many chronic conditions. This study aimed to develop an unidimensional NP scale with scores that represent levels of NP and distinguish between individuals with NP and non-NP conditions. METHODS: A candidate item pool of 42 pain quality descriptors was administered to participants with osteoarthritis, rheumatoid arthritis, diabetic neuropathy, and cancer chemotherapy-induced peripheral neuropathy. A subset of pain quality descriptors (items) that best distinguished between participants with and those without NP conditions were identified...
July 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27563006/anti-nociceptive-roles-of-the-glia-specific-metabolic-inhibitor-fluorocitrate-in-paclitaxel-evoked-neuropathic-pain
#15
Yongming Xu, Guangxia Cheng, Yanrong Zhu, Xin Zhang, Shaofeng Pu, Junzhen Wu, Yingying Lv, Dongping Du
Paclitaxel (Taxol) is a powerful chemotherapy drug used in breast cancers, but it often causes neuropathic pain, leading to the early cessation of therapy and poor treatment outcomes. Approaches for the management of paclitaxel-induced neuropathic pain are urgently needed. The involvement of spinal astrocytes in the pathogenesis of paclitaxel-induced neuropathy has been reported, but little is known about the role of fluorocitrate (FC), a selective inhibitor of astrocyte activation, during neuropathic pain related to paclitaxel treatment...
October 2016: Acta Biochimica et Biophysica Sinica
https://www.readbyqxmd.com/read/27539464/the-use-of-low-level-light-therapy-in-supportive-care-for-patients-with-breast-cancer-review-of-the-literature
#16
Jolien Robijns, Sandrine Censabella, Paul Bulens, Annelies Maes, Jeroen Mebis
Breast cancer is the most common cancer in women worldwide, with an incidence of 1.7 million in 2012. Breast cancer and its treatments can bring along serious side effects such as fatigue, skin toxicity, lymphedema, pain, nausea, etc. These can substantially affect the patients' quality of life. Therefore, supportive care for breast cancer patients is an essential mainstay in the treatment. Low-level light therapy (LLLT) also named photobiomodulation therapy (PBMT) has proven its efficiency in general medicine for already more than 40 years...
August 19, 2016: Lasers in Medical Science
https://www.readbyqxmd.com/read/27534963/comparison-of-oxaliplatin-and-paclitaxel-induced-neuropathy-alliance-a151505
#17
Deirdre R Pachman, Rui Qin, Drew Seisler, Ellen M Lavoie Smith, Suneetha Kaggal, Paul Novotny, Kathryn J Ruddy, Jacqueline M Lafky, Lauren E Ta, Andreas S Beutler, Nina D Wagner-Johnston, Nathan P Staff, Axel Grothey, Patrick M Dougherty, Guido Cavaletti, Charles L Loprinzi
PURPOSE: Oxaliplatin and paclitaxel are commonly used chemotherapies associated with acute and chronic neuropathies. There is a need to better understand the similarities and differences of these clinical syndromes. METHODS: Neuropathy data were pooled from patients receiving adjuvant oxaliplatin and weekly paclitaxel or every 3 weeks of paclitaxel. Patients completed daily questionnaires after each chemotherapy dose and the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for patients with chemotherapy-induced peripheral neuropathy before each chemotherapy cycle and for 12 months post-treatment...
August 18, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27475880/neuropathic-pain-in-cancer-patients-treated-with-bortezomib
#18
S Expósito Vizcaíno, J Casanova-Mollà, L Escoda, S Galán, J Miró
INTRODUCTION: The neuropathic pain is the most habitual problem in the neuropathy induced by chemotherapy (NIQ) and the one that more interferes in the quality of life of the patients. His precocious detection turns out to be fundamental to reduce or to eliminate the problems that from this one stem. The aims of this study were: 1) determine the incident and NIQ's characteristics and neuropathic pain in patients with mieloma multiple (MM) treated with bortezomib, and 2) to evaluate the impact of the neuropathic pain in the activities of the daily life (AVD)...
July 27, 2016: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/27470258/evaluating-the-impact-of-chemotherapy-induced-peripheral-neuropathy-symptoms-cipn-sx-on-perceived-ability-to-work-in-breast-cancer-survivors-during-the-first-year-post-treatment
#19
Noah R Zanville, Kelly N H Nudelman, Dori J Smith, Diane Von Ah, Brenna C McDonald, Victoria L Champion, Andrew J Saykin
PURPOSE: To describe the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on breast cancer survivors' (BCS) perceived ability to work post-treatment. METHODS: The sample included 22 chemotherapy-treated (Ctx+) and 22 chemotherapy-naïve (Ctx-) female BCS. Data was collected at the following three time points: baseline (post-surgery, pre-chemotherapy), 1 month (1 M) post-chemotherapy, and approximately 1 year (1 Y) later. The presence, frequency, number, and severity of CIPN-sx were self-reported using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire (FACT/GOG-Ntx) version 4, a validated 11-item CIPN measure...
November 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27400948/randomized-phase-iii-trial-of-irinotecan-plus-cisplatin-compared-with-paclitaxel-plus-carboplatin-as-first-line-chemotherapy-for-ovarian-clear-cell-carcinoma-jgog3017-gcig-trial
#20
Toru Sugiyama, Aikou Okamoto, Takayuki Enomoto, Tetsutaro Hamano, Eriko Aotani, Yasuhisa Terao, Nao Suzuki, Mikio Mikami, Nobuo Yaegashi, Kiyoko Kato, Hiroyuki Yoshikawa, Yoshihito Yokoyama, Hiroshi Tanabe, Koji Nishino, Hiroyuki Nomura, Jae-Weon Kim, Byoung-Gie Kim, Sandro Pignata, Jerome Alexandre, John Green, Seiji Isonishi, Fumitoshi Terauchi, Keiichi Fujiwara, Daisuke Aoki
PURPOSE: Clear cell carcinoma (CCC) is a rare histologic subtype that demonstrates poor outcomes in epithelial ovarian cancer. The Japanese Gynecologic Oncology Group conducted the first randomized phase III, CCC-specific clinical trial that compared irinotecan and cisplatin (CPT-P) with paclitaxel plus carboplatin (TC) in patients with CCC. PATIENTS AND METHODS: Six hundred sixty-seven patients with stage I to IV CCC of the ovary were randomly assigned to receive irinotecan 60 mg/m(2) on days 1, 8, and 15 plus cisplatin 60 mg/m(2) on day 1 (CPT-P group) every 4 weeks for six cycles or paclitaxel 175 mg/m(2) plus carboplatin area under the curve 6...
August 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
76402
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"